01—Abstract
Summary
Summary of the 8-K filed May 28, 2024. Cited figures are marked; the original filing is the authoritative source.
On May 28, 2024, Neurocrine Biosciences, Inc. ("Neurocrine") announced that Kevin C.
Gorman, Ph.D. will retire as President and Chief Executive Officer effective October 11, 2024 (the "Transition Date"). Dr. Gorman notified the company of his planned retirement on May 24, 2024, and will remain on the Board of Directors as a member. The company also announced that Kyle Gano, Ph.D., age 51, will succeed him as President and Chief Executive Officer effective on the Transition Date.
Dr. Gano will also join the Board as a Class II director, to serve until the 2025 annual meeting of stockholders. The filing states that he has served as Chief Business Development Officer since 2011 and as Chief Business Development and Strategy Officer since 2020, with responsibility for all business and corporate development activities, including collaborations with AbbVie, Mitsubishi Tanabe Pharma, Takeda, Xenon Pharmaceuticals, Voyager Therapeutics, and others. He joined Neurocrine in 2001.
Effective on the Transition Date, the Board amended Section 3.2 of the Bylaws to increase the authorized size of the Board from ten to eleven members, with the new seat filled by Dr. Gano's appointment. The amendment is filed as Exhibit 3.1.
02—Key points
Key Highlights
- Kevin C. Gorman, Ph.D. will retire as President and CEO effective October 11, 2024, and will remain on the Board of Directors.
- Kyle Gano, Ph.D., age 51, will become President and CEO effective October 11, 2024.
- Dr. Gano will join the Board as a Class II director, serving until the 2025 annual meeting of stockholders.
- Dr. Gano has been Chief Business Development Officer since 2011 and Chief Business Development and Strategy Officer since 2020, and oversees all business and corporate development activities.
- Dr. Gorman notified the company of his planned retirement on May 24, 2024.
- The Board will increase from ten to eleven authorized members effective on the Transition Date, with Dr. Gano filling the new seat.
- The Bylaws amendment is filed as Exhibit 3.1 (Certificate of Amendment of Bylaws).
03—Questions
Frequently Asked Questions
Who is replacing Kevin Gorman as CEO of Neurocrine Biosciences?
Kyle Gano, Ph.D., who has served as Chief Business Development and Strategy Officer, will succeed Dr. Gorman as President and Chief Executive Officer effective October 11, 2024.
Will Kevin Gorman leave the Board of Directors?
No. The filing states that Dr. Gorman will continue to serve as a member of Neurocrine's Board of Directors after he retires as CEO.
What is Kyle Gano's background at Neurocrine?
The filing states that Dr. Gano joined Neurocrine in 2001 and held positions spanning marketing analytics to business development. He was appointed Chief Business Development Officer in 2011 and Chief Business Development and Strategy Officer in 2020, and manages the company's collaborations, including those with AbbVie, Takeda, and Xenon Pharmaceuticals.
How is the Board of Directors changing?
Effective October 11, 2024, the Board will increase from ten to eleven authorized members. Dr. Gano will fill the new seat as a Class II director until the 2025 annual meeting of stockholders.
When do the leadership changes take effect?
The changes take effect on the Transition Date, October 11, 2024, as defined in the filing.
04—Continue